A5015825372- Multiple Myeloma Research and Treatments
- Chronic Lymphocytic Leukemia Research
- Protein Degradation and Inhibitors
- Pregnancy and preeclampsia studies
- Immunodeficiency and Autoimmune Disorders
- Glycosylation and Glycoproteins Research
- Neonatal Respiratory Health Research
- Acute Myeloid Leukemia Research
- Cancer Genomics and Diagnostics
- Diagnosis and treatment of tuberculosis
- Mycobacterium research and diagnosis
- Tuberculosis Research and Epidemiology
- Peptidase Inhibition and Analysis
- Amyloidosis: Diagnosis, Treatment, Outcomes
- Blood groups and transfusion
- Blood disorders and treatments
- Gastrointestinal disorders and treatments
- Chemokine receptors and signaling
- Maternal and fetal healthcare
- Cancer Mechanisms and Therapy
- Histone Deacetylase Inhibitors Research
- Neutropenia and Cancer Infections
- Cancer-related Molecular Pathways
- Musculoskeletal pain and rehabilitation
- Telomeres, Telomerase, and Senescence
Wilkes-Barre VA Medical Center
2025
Ospedale Maggiore
2012-2025
Istituti di Ricovero e Cura a Carattere Scientifico
2012-2025
University of Milan
2011-2024
Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico
2012-2024
IRCCS Materno Infantile Burlo Garofolo
2022
University Hospital Brno
2019
United States Department of Veterans Affairs
1954
// Marta Lionetti 1 , Marzia Barbieri 2 Katia Todoerti 3 Luca Agnelli Simona Marzorati Sonia Fabris Gabriella Ciceri Serena Galletti Giulia Milesi Martina Manzoni Mara Mazzoni 4 Angela Greco Giovanni Tonon 5 Pellegrino Musto Baldini 1,2 and Antonino Neri Department of Clinical Sciences Community Health, University Milan, Italy Hematology Unit, Fondazione IRCCS Ca’ Granda, Ospedale Maggiore Policlinico, Laboratory Pre-Clinical Translational Research, IRCCS-CROB, Referral Cancer Center...
Primary plasma cell leukemia (pPCL) is a rare, yet aggressive form of de novo tumor, distinct from secondary PCL (sPCL) which represents leukemic transformation pre-existing multiple myeloma (MM). Herein, we performed comprehensive molecular analysis prospective series pPCLs by means FISH, single nucleotide polymorphism (SNP) array and gene expression profiling (GEP). IGH@ translocations were identified in 87% pPCL cases, with prevalence t(11;14) (40%) t(14;16) (30.5%), whereas the most...
The purpose of this study was to better characterize morphine equivalent daily dose (MEDD) equivalencies with buccal buprenorphine, and identify real-world efficacy safety outcomes associated the use buprenorphine for chronic pain at a local VA Medical Center. This retrospective chart review Computerized Patient Record System (CPRS) patient records outpatient prescriptions (Belbuca®). Overall, there high discontinuation rate Belbuca®: being 60% or greater across all different groups. These...
Multiple Myeloma is driven by clonal plasma cell (cPC)-intrinsic factors and changes in the tumorigenic microenvironment (TME). To investigate if residual polyclonal PCs (pPCs) are disrupted, single-cell (sc) RNAseq sc B-cell receptor analysis were applied a cohort of 46 samples with PC dyscrasias 21 healthy donors (HDs). Out n=234,789 PCs, 64,432 genotypically identified as pPCs frequencies decreasing over different disease stages, from 23.66% monoclonal gammopathy undetermined significance...
Multiple myeloma (MM) initiation is dictated by genomic events. However, its progression from asymptomatic stages to an aggressive disease that ultimately fails respond treatments also dependent on changes of the tumor microenvironment (TME). Clonal hematopoiesis indeterminate potential (CHIP) a prevalent clonal condition hematopoietic stem cell whose presence causally linked more inflamed microenvironment. Here, we show in 106 patients with MM CHIP frequently co-existing at diagnosis,...
The prevalence of TP53 mutations greatly varies between tumor types; in multiple myeloma (MM) they were rarely detected at presentation, while increased frequency was reported with disease progression. Using next-generation sequencing, we analyzed exons 4-9 a large representative cohort comprising patients MM diagnosis and more aggressive forms plasma cell (PC) dyscrasia, identifying 4/129 (3%) MM, 6/24 (25%) primary PC leukemia, 2/10 (20%) secondary leukemia cases. A similar increase...
// Marta Lionetti 1, 2 * , Marzia Barbieri Katia Todoerti 3 Luca Agnelli Sonia Fabris Giovanni Tonon 4 Simona Segalla Ingrid Cifola 5 Eva Pinatel Pierfrancesco Tassone 6 Pellegrino Musto Baldini and Antonino Neri 1 Department of Clinical Sciences Community Health, University Milano, Milan, Italy Hematology Unit, Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico, Laboratory Pre-Clinical Translational Research, IRCCS-CROB, Referral Cancer Center Basilicata, Rionero in Vulture (PZ),...
Low-risk myelodysplastic syndromes (LR-MDS) are a very heterogeneous disease, with extremely variable clinical features and outcome. Therapeutic strategies still limited mainly consist of erythropoiesis-stimulating agents (ESAs) transfusion support. The contribution molecular lesions autoimmune phenomena to pathogenesis course, including leukemic evolution, is field open investigation. We analyzed data from cohort 226 patients LR-MDS followed at our center in the last 20 years, focusing on...
Multiple myeloma is still incurable due to an intrinsic aggressiveness or, more frequently, the interactions of malignant plasma cells with bone marrow (BM) microenvironment. Myeloma educate BM support neoplastic cell growth, survival, acquisition drug resistance resulting in disease relapse. microenvironment characterized by Notch signaling hyperactivation increased expression Notch1 and 2 ligands Jagged1 tumor cells. activation influences biology promotes reprogramming stromal In this work...
Recent studies have described chromosome 2p gain as a recurrent lesion in chronic lymphocytic leukemia (CLL). We investigated the and its relationship with common prognostic biomarkers prospective series of 69 clinical monoclonal B-cell lymphocytosis (cMBL) 218 early stage (Binet A) CLL patients. The was detected by FISH 17 patients (6%, 16 CLL, 1 cMBL) further characterized single nucleotide polymorphism-array. Overall, unfavorable cytogenetic deletions, i.e., del(11)(q23) del(17)(p13) (P =...
IGF1R is emerging as an important gene in the pathogenesis of many solid and haematological cancers its over-expression has been reported frequently associated with aggressive disease chemotherapy resistance. In this study we performed investigation role expression a large representative prospective series 217 chronic lymphocytic leukaemia (CLL) patients enrolled multicentre O-CLL1 protocol (clinicaltrial.gov #NCT00917540). High was significantly IGHV unmutated (IGHV-UM) status (p<0.0001),...
Abstract Chronic lymphocytic leukaemia (CLL) is characterised by a heterogeneous clinical course. Such heterogeneity associated with number of markers, including TP53 gene inactivation. While alterations determine resistance to chemotherapy, it not clear whether they can influence early disease progression. To clarify this issue, mutations and deletions the corresponding locus [del(17p)] were evaluated in 469 cases from O-CLL1 observational study that recruited cohort clinically molecularly...
SUMMARY Multiple Myeloma (MM) is driven by clonal plasma cell (PC)-intrinsic factors and changes in the tumorigenic microenvironment (TME). To investigate if residual polyclonal PCs (pPCs) are disrupted, single-cell (sc) RNAseq sc B-cell receptor analysis were applied a cohort of 46 samples with PC dyscrasias 18 healthy donors (HDs). Out n= 213,074 CD138 pos PCs, 42,717 genotypically identified as pPCs. Compared to HDs, we detected quantitative qualitative differences pPCs patients showing...
Smoldering multiple myeloma (SMM) is an asymptomatic plasma cell (PC) neoplasm that may evolve with variable frequency into (MM). SMM initiated by chromosomal translocations involving the immunoglobulin heavy-chain locus or hyperdiploidy and evolves through acquisition of additional genetic lesions. In this scenario, we aimed at establishing a reliable analysis pipeline to infer genomic lesions from transcriptomic analysis, combining single-cell RNA sequencing (scRNA-seq) B-cell receptor...